Agriculture company Calyxt Inc (NASDAQ: CLXT) announced on Thursday that it plans to crush and produce its high oleic soybean variety through an agreement with American Natural Processors (ANP), a leading provider of innovative non-GMO and organic processing of oils, flours and meals in Cherokee, Iowa.
ANP will crush Calyxt's high-oleic soybean variety and produce its first high oleic consumer soybean oil, which is expected to hit the market in late 2018 / early 2019.
In conjunction, the high-oleic / low-saturated fat oil from Calyxt's new variety of soybeans is designed to eliminate the need for hydrogenation, a process that improves heat stability and shelf life of conventional soybean oil. The process of hydrogenation for conventional soybean oil contributes to the production of trans-fatty acids, which, when consumed, raises low-density lipoprotein, or LDL, and cholesterol levels, as well as contributes to cardiovascular diseases.
Additionally, Calyxt has received a letter from the USDA confirming that its high-oleic soybean variety is non-regulated, as the product contains no foreign DNA.
The US FDA has declared trans fats not generally recognised as safe (GRAS) and human food must no longer contain partially hydrogenated oils by 18 June 2018. The World Health recently unveiled a plan to remove all trans fats worldwide from the food chain by 2023.
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies
CirCode Biomed's IND application for HM2002 receives FDA clearance
CeleCor Therapeutics completes Phase 3 trial of new anti-platelet agent for heart attack
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
Ionis reports positive Phase 3 results for olezarsen in moderate hypertriglyceridemia
Nordic Bioscience launches new Endotrophin assay
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment